Discover

PODD
Insulet Corporation
189.56
1 x 187.82
1 x 188.90
bid
ask
-
2.65
1.38%
1 @ 04:00 PM
192.99 +3.43 (1.81%)
Ytd -33.31%
1y -26.92%
186.25
day range
190.68
189.56
52 week range
352.82
Open 188.85 Prev Close 192.21 Low 186.25 High 190.68 Mkt Cap 13.13B
Vol 1.08M Avg Vol 1.01M EPS 3.43 P/E 55.27 Forward P/E 23.79
Beta 1.47 Short Ratio 3.13 Inst. Own 105.27% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 05-06 50-d Avg 224.19 200-d Avg 285.48 1yr Est 333.30
Earning
Date For Estimate Reported Surprise surprise %
2026-05-06 2026-03 1.14 N/A N/A N/A
2026-02-18 2025-12 1.48 1.55 0.07 4.73%
2025-11-06 2025-09 1.13 1.24 0.11 9.73%
2025-08-07 2025-06 0.93 1.17 0.24 25.81%
2025-05-08 2025-03 0.81 1.02 0.21 25.93%
2025-02-20 2024-12 1.05 1.15 0.1 9.52%
Upgrade / Downgrade
Date Firm Action From To
2026-04-24 Rothschild & Co Downgrade Buy Neutral
2026-04-15 Truist Securities Upgrade Buy Buy
2026-04-09 Goldman Sachs Upgrade Buy Buy
2026-04-07 Citigroup Downgrade Buy Neutral
2026-03-11 Citigroup Upgrade Buy Buy
2026-02-19 Citigroup Upgrade Buy Buy
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-02-23 BENJAMIN ERIC Chief Operating Officer 24.51K Stock Award(Grant)
2025-02-24 CHADWICK ANA MARIA Chief Financial Officer 16.03K Stock Award(Grant)
2025-02-24 FIELD MARK N Chief Technology Officer 13.92K Stock Award(Grant)
2025-02-24 HOLLINGSHEAD JAMES R Chief Executive Officer 68.07K Stock Award(Grant)
2025-05-21 HOPFIELD JESSICA Director 27.70K Stock Award(Grant)
2026-02-23 KAPPLES JOHN W. General Counsel 28.12K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 8.70M 1.65B 12.56%
2025-12-30 Blackrock Inc. 6.58M 1.25B 9.50%
2025-12-30 FMR, LLC 6.33M 1.20B 9.13%
2025-12-30 Capital Research Global Investors 4.41M 835.76M 6.37%
2025-12-30 State Street Corporation 3.16M 598.15M 4.56%
2025-12-30 BAILLIE GIFFORD & CO 2.05M 388.29M 2.96%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 2.22M 420.48M 3.20%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 1.77M 336.26M 2.56%
2026-02-27 Fidelity Securities Fund-Fidelity OTC Portfolio 904.48K 171.45M 1.31%
2026-03-30 AMCAP FUND 900.00K 170.60M 1.30%
2026-02-27 Fidelity Concord Street Trust-Fidelity 500 Index Fund 895.26K 169.70M 1.29%
2026-02-27 iShares Trust-iShares Core S&P 500 ETF 896.08K 169.86M 1.29%